Winners / 2023

Moderna’s bivalent COVID-19 booster vaccine (mRNA-1273.222)

By: Moderna
Gold

Master Category:

Award Category: Health, Medical & Biotech

Award Sub-Category: Advanced Drug Delivery

Moderna’s BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster (mRNA-1273.22) targets the original strain of SARS-CoV-2 and BA.4/BA.5 Omicron subvariants. It was developed per U.S. FDA guidance to protect against COVID-19 variants for fall and winter 2022. mRNA-1273.222 is authorized in the U.S., UK, EU and other countries.

Explore more Health & Wellness

Put your innovation in the spotlight.

For four decades, the Edison Awards have recognized innovative products, services, and technologies that create meaningful value and impact. Explore the categories, find the right fit, and enter your new innovation for recognition.

Ready for Nomination Season?

Complete the form below to download the 2027 Nomination Guide.

A Founders Guide to Modern Innovation
The Future of the Grid – Panel Discussion 2024 Edison Awards
Edison Award-Winning Brain Technology Featured in U.S. News & World Report